New drug combo targets deadly thyroid cancer in small trial

NCT ID NCT06374602

Recruiting now Disease control Sponsor: Saint Petersburg State University, Russia Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 2 trial is testing whether two drugs, pembrolizumab and lenvatinib, can shrink tumors and improve survival in 20 people with anaplastic thyroid cancer, a rare and fast-growing cancer. Participants will receive both drugs and be monitored for response and side effects. The study aims to see if the combination can make inoperable tumors removable by surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pembrolizumab and lenvatinib
What this could lead to: If successful, this combination could offer a new treatment option for anaplastic thyroid cancer, potentially shrinking tumors and extending survival.
What could go wrong: This is a small, early-phase trial with only 20 participants. The drugs may cause significant side effects, and the results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANAPLASTIC THYROID CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

thyroid gland undifferentiated (anaplastic) carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANAPLASTIC THYROID CANCER

Contacts and locations

Locations

Saint Petersburg State University Hospital
RECRUITING

Saint Petersburg, 190020, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.